摘要
目的:探讨类风湿关节炎患者经青白通痹胶囊治疗后28个关节疾病活动度评分(DAS28)及血液相关指标水平变化情况,旨在为临床上更好地治疗类风湿关节炎提供参考。方法:选取我院2018年1月至2020年1月期间接受治疗的80例类风湿关节炎患者作为研究对象,采用随机数字表法分为两组:对照组(n=40)患者采用来氟米特治疗,观察组(n=40)患者采用来氟米特联合青白通痹胶囊治疗。两组患者均持续治疗3个月,观察两组患者DAS28评分、治疗效果、血液相关指标水平变化情况、疼痛程度和不良反应。结果:与对照组比较,观察组患者治疗后DAS28评分更低(P<0.05),临床治疗效果更佳;与对照组比较,观察组患者血液相关指标血沉(ESP)、C反应蛋白(CRP)及类风湿因子(RF)水平均更低(P<0.05);与对照组比较,观察组患者经治疗后不良反应更少,疼痛VAS评分更低(P<0.05)。结论:给予类风湿关节炎患者青白通痹胶囊,可有效缓解患者的疾病进展,降低其疼痛感,稳定其血液指标水平,同时还能提高治疗的安全性,治疗效果显著。
Objective:To investigate the DAS28 score and blood-related index levels changing situation of patients with rheumatoid arthritis treated with qingbaitongbi capsule,to provide references for the clinical treatment of rheumatoid arthritis.Methods:80 patients with rheumatoid arthritis treated in our hospital from January 2018 to January 2020 were selected as research objects,and they were divided into two groups by random number table method.The control group(n=40)was treated with leflunomide and the observation group(n=0)was treated with leflunomide combined with qingbaitongbi capsule.The two groups were given continued treatment for 3 months.Observe the patient′s DAS28 score,treatment effect,blood-related index levels changing situation,pain degree and adverse reactions.Results:Compared with the control group,DAS28 score in the observation group was lower after treatment(P<0.05),and clinical treatment effect was better.Compared with the control group,the blood-related index level of the ESP,CRP and RF in the observation group were lower(P<0.05).Compared with the control group,the VAS score in the observation group was lower after treatment(P<0.05),and adverse reactions were less.Conclusion:Qingbaitongbi capsules for rheumatoid arthritis patients can effectively alleviate the patient′s disease progression,reduce their pain,stabilize their blood index levels,and at the same time improve the safety of the treatment,and the treatment effect is significant.
作者
张冠杰
胡筱娟
朱海慧
程红卫
魏长征
ZHANG Guanjie;HU Xiaojuan;ZHU Haihui;CHENG Hongwei;WEI Changzheng(Shaanxi Provincial Hospital of Traditional Chinese Medicine, Shaanxi Xi′an 710021, China;The Fifth Hospital of Xi′an, Shaanxi Xi′an 710082, China)
出处
《中国医药导刊》
2021年第7期496-499,共4页
Chinese Journal of Medicinal Guide
基金
陕西省重点研发计划项目(项目编号:2017SF-333,项目名称:青白通痹胶囊治疗类风湿性关节炎的临床研究)。
关键词
青白通痹胶囊
类风湿关节炎
病情评价
疼痛程度
血沉
C反应蛋白
类风湿因子
Qingbaitongbi capsule
Rheumatoid arthritis
Disease evaluation
Pain degree
Erythrocyte sedimentation rate
C-reactive protein
Rheumatoid factor
